Vaxcyte PCVX Stock
Vaxcyte Price Chart
Vaxcyte PCVX Financial and Trading Overview
| Vaxcyte stock price | 73.02 USD |
| Previous Close | 52.4 USD |
| Open | 52.3 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 51.76 - 52.59 USD |
| 52 Week Range | 18.91 - 54.84 USD |
| Volume | 400.51K USD |
| Avg. Volume | 946K USD |
| Market Cap | 4.89B USD |
| Beta (5Y Monthly) | 0.956114 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.8 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.29 USD |
PCVX Valuation Measures
| Enterprise Value | 4.08B USD |
| Trailing P/E | N/A |
| Forward P/E | -15.564179 |
| PEG Ratio (5 yr expected) | -14.5 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.4503245 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -15.603 |
Trading Information
Vaxcyte Stock Price History
| Beta (5Y Monthly) | 0.956114 |
| 52-Week Change | 158.24% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 54.84 USD |
| 52 Week Low | 18.91 USD |
| 50-Day Moving Average | 46.95 USD |
| 200-Day Moving Average | 40.64 USD |
PCVX Share Statistics
| Avg. Volume (3 month) | 946K USD |
| Avg. Daily Volume (10-Days) | 464.37K USD |
| Shares Outstanding | 93.71M |
| Float | 82.88M |
| Short Ratio | 8.99 |
| % Held by Insiders | 4.07% |
| % Held by Institutions | 90.54% |
| Shares Short | 7.07M |
| Short % of Float | 8.52% |
| Short % of Shares Outstanding | 7.53% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.41% |
| Return on Equity (ttm) | -37.56% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -22995000 USD |
| EBITDA | -261520000 USD |
| Net Income Avi to Common (ttm) | -244960992 USD |
| Diluted EPS (ttm) | -3.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 822.04M USD |
| Total Cash Per Share (mrq) | 8.77 USD |
| Total Debt (mrq) | 16.59M USD |
| Total Debt/Equity (mrq) | 1.76 USD |
| Current Ratio (mrq) | 15.938 |
| Book Value Per Share (mrq) | 11.716 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -190584992 USD |
| Levered Free Cash Flow (ttm) | -120237128 USD |
Profile of Vaxcyte
| Country | United States |
| State | CA |
| City | San Carlos |
| Address | 825 Industrial Road |
| ZIP | 94070 |
| Phone | 650 837 0111 |
| Website | https://vaxcyte.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 158 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Q&A For Vaxcyte Stock
What is a current PCVX stock price?
Vaxcyte PCVX stock price today per share is 73.02 USD.
How to purchase Vaxcyte stock?
You can buy PCVX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vaxcyte?
The stock symbol or ticker of Vaxcyte is PCVX.
Which industry does the Vaxcyte company belong to?
The Vaxcyte industry is Biotechnology.
How many shares does Vaxcyte have in circulation?
The max supply of Vaxcyte shares is 128.76M.
What is Vaxcyte Price to Earnings Ratio (PE Ratio)?
Vaxcyte PE Ratio is now.
What was Vaxcyte earnings per share over the trailing 12 months (TTM)?
Vaxcyte EPS is -3.8 USD over the trailing 12 months.
Which sector does the Vaxcyte company belong to?
The Vaxcyte sector is Healthcare.
Vaxcyte PCVX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18847.28 USD — |
+1.63
|
7.42B USD — | 18372.99 USD — | 18861.33 USD — | — - | 7.42B USD — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2311.68 USD — |
+1.12
|
— — | 2267.96 USD — | 2311.94 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 9220.93 USD — |
+1.64
|
— — | 8989.31 USD — | 9228.07 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4518.06 USD — |
+1.34
|
— — | 4444.3 USD — | 4518.85 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 1010.47 USD — |
+1.04
|
— — | 993.66 USD — | 1010.65 USD — | — - | — — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1497.75 USD — |
+1.39
|
— — | 1475.11 USD — | 1498.84 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4486.38 USD — |
-0.37
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}